Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.67 |
| ▸ | MET | P08581 | 16/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.58 |
| ▸ | FLT4 | P35916 | 2/20 | 0.58 |
| ▸ | TEK | Q02763 | 2/20 | 0.58 |
| ▸ | MST1R | Q04912 | 2/20 | 0.58 |
| ▸ | BTK | Q06187 | 2/20 | 0.58 |
| ▸ | FLT3 | P36888 | 3/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | INSR | P06213 | 2/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | STK25 | O00506 | 1/20 | 0.58 |
| ▸ | CIT | O14578 | 1/20 | 0.58 |
| ▸ | CHUK | O15111 | 1/20 | 0.58 |
| ▸ | MUSK | O15146 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855812 | 0.86 | AXL (0.74) | AXLMETKDREGFRAURKA | |
| SCHEMBL13511878 | 0.84 | AXL (0.73) | AXLMETKDREGFRAURKA | |
| SCHEMBL2858708 | 0.83 | AXL (0.66) | AXLMETKDREGFRAURKA | |
| SCHEMBL2868773 | 0.83 | AXL (0.66) | AXLMETKDREGFRAURKA | |
| SCHEMBL2856104 | 0.83 | AXL (0.66) | AXLMETKDREGFRAURKA | |
| SCHEMBL2868781 | 0.82 | AXL (0.66) | AXLMETKDREGFRAURKA | |
| SCHEMBL16069960 | 0.81 | AXL (0.79) | AXLMETKDREGFRAURKA | |
| SCHEMBL2868384 | 0.81 | AXL (0.69) | AXLMETKDREGFRAURKA | |
| SCHEMBL2861187 | 0.81 | AXL (0.65) | AXLMETKDREGFRAURKA | |
| SCHEMBL2856001 | 0.81 | AXL (0.65) | AXLMETKDREGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | claimed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | AXL 304/4885MET 563/4885KDR 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.